Table 2.
Significance of clinicopathologic parameters and TIL markers for survival
| Univariate | p value | Multivariate | p value | |
|---|---|---|---|---|
| 3-Year survival | HR (95% CI) | |||
| OS | ||||
| ECE (Yes vs. No) | 46.2% vs. 94.4% | 0.000 | 19.713 (2.594–149.833) | 0.004 |
| N classification (N2/N3 vs. N0/N1) | 56.8% vs. 93.4% | 0.001 | 6.473 (1.465–28.609) | 0.014 |
| Margin (Close/Positive vs. Negative) | 60.6% vs. 80.8% | 0.054 | ||
| Stage (early vs. advanced) | 94.7% vs. 66.4% | 0.009 | ||
| CD8/FOXP3 (High vs. Low) | 87.3% vs. 63.8% | 0.006 | 0.115 (0.017–0.791) | 0.028 |
| LRFS | ||||
| Differentiation (Moderate/Poor vs. Well) | 58.5% vs. 93.3% | 0.017 | 8.679 (1.127–66.871) | 0.038 |
| Gender (Male vs. Female) | 70.9% vs. 100% | 0.019 | ||
| Margin (Close/Positive vs. Negative) | 66.9% vs. 85.8% | 0.030 | ||
| ECE (Yes vs. No) | 66.4% vs. 79.0% | 0.095 | ||
| RRFS | ||||
| ECE (Yes vs. No) | 57.8% vs. 86.0% | 0.018 | 5.268 (1.503–18.466) | 0.022 |
| N classification (N2/N3 vs. N0/N1) | 65.2% vs. 81.7% | 0.098 | 16.335 (1.484–179.799) | 0.024 |
| Differentiation (Moderate/Poor vs. Well) | 57.7% vs. 88.2% | 0.059 | ||
| CD8 (Low vs. High) | 65.9% vs. 83.2% | 0.069 | ||
| FOXP3 (High vs. low) | 49.3% vs. 87.3% | 0.000 | 7.487 (1.786–31.395) | 0.006 |
| CD8/FOXP3 (High vs. Low) | 84.1% vs. 61.8% | 0.014 | ||
| DMFS | ||||
| ECE (Yes vs. No) | 66.8% vs. 94.4% | 0.007 | 3.929 (0.489–31.590) | 0.042 |
| N classification (N2/N3 vs. N0/N1) | 70.3% vs. 97.1% | 0.003 | 2.980 (0.370–24.033) | 0.035 |
| Stage (early vs. advanced) | 100% vs. 72.0% | 0.005 | ||
| CD3/CD4 (High vs. Low) | 70.2% vs. 90.5% | 0.026 | ||
| CD4/FOXP3 (High vs. Low) | 93.7% vs. 68.4% | 0.002 | 0.032 (0.003–0.384) | 0.007 |
Abbreviation: Advanced stage 4, CI confidence interval, DMFS distant metastasis free survival, Early stage stage 1/2/3, ECE extracapsular extension, HR hazard ratio, LRFS local recurrence free survival, OS overall survival, RRFS regional recurrence free survival